Business briefing - key facts


- AstraZeneca is one of the world's leading pharmaceutical companies.
- We provide innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory.
- Our broad product portfolio includes many world leaders and a range of high potential therapies for treating cancer (Casodex, Arimidex and Faslodex), gastrointestinal disease ( Nexium), asthma ( Symbicort), hypertension ( Atacand), high cholesterol ( Crestor), migraine ( Zomig) and schizophrenia ( Seroquel).
- Our products are available in over 100 countries.
- Sales in 2006 totalled $26.5 billion with an operating profit of $8.2 billion.
- We are committed to continued top tier financial performance alongside continued innovation.
- We spend over $16 million every working day on the research and development of new medicines that meet patient needs. (Total R&D spend in 2006: $3.9 billion).
- We employ 12,000 people in research and development at 12 R&D centres in 8 countries.
- We have 27 manufacturing sites in 19 countries dedicated to ensuring we can deliver a secure, high quality, cost-effective supply of our product range around the world.
- In total, we employ over 66,000 people worldwide: 58% in Europe, 27% in the Americas and 15% in the rest of the world.
- Our corporate headquarters are in London, UK and our R&D headquarters are in Sodertalje, Sweden.
- We combine our global capabilities with high quality relationships in local markets and focus on responding quickly and effectively to changing business needs.
- With a global business comes a global responsibility and, along with our commitment to competitiveness and performance, we will continue to be led by our core values to achieve sustainable success.
This page was last rendered at: Mon Jul 02 11:23:03 GMT+01:00 2007
This page was last published at: 3/19/2008 5:07:30 PM
Target:
Category:
URL: /ideas/aboutus/ourbusiness.asp
|